anti-PSMA antibody-drug conjugates (Medarex)

N/A

Report date: 2025/03/18 20:00:05

Base Information

Drug Nameanti-PSMA antibody-drug conjugates (Medarex)
Drug Alias Nameanti-PSMA-MED-2220 conjugates (Medarex)duocarmycin analog-anti-PSMA antibody conjugates (Medarex)anti-PSMA ADCs (Medarex)duocarmycin analog-antibody conjugates (Medarex)
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC)Biologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Monoclonal antibody conjugateBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody conjugate
Mechanisms of ActionProstate-Specific Membrane Antigen modulators
TargetsProstate-Specific Membrane Antigen
Therapy Area/IndicationsProstatic Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesMedarex Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesMedarex Inc
Active IndicationsN/A
Inactive IndicationsProstatic Neoplasms

Other Information

ATC CodeN/A
Related LinksN/A